Status:
TERMINATED
Placebo Controlled Dose-Response Study Of PD-217,014 In The Treatment Of Postherpetic Neuralgia
Lead Sponsor:
Pfizer
Conditions:
Pain
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine the effectiveness of PD-217,014 in the treatment of chronic pain following a shingles infection.
Eligibility Criteria
Inclusion
- Patients must have pain present for more than 3 months after the healing of shingles skin rash.
- Patients at screening must have a score \>=40 mm on the pain visual analogue scale.
Exclusion
- Patients with poor renal function.
- Patients with other severe pain, that may impair the self-assessment of the pain due to shingles.
- Patients with abnormal electrocardiogram.
Key Trial Info
Start Date :
February 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
315 Patients enrolled
Trial Details
Trial ID
NCT00159640
Start Date
February 1 2004
Last Update
March 28 2007
Active Locations (32)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Warrawong, New South Wales, Australia
2
Pfizer Investigational Site
Westmead, New South Wales, Australia
3
Pfizer Investigational Site
Kippa-Ring, Queensland, Australia
4
Pfizer Investigational Site
Maroochydore, Queensland, Australia